On July 23, 2025, two Shenzhen-based Vape giants—YOUME Technology and IVPS—lost their appeals in the U.S. Fifth Circuit Court of Appeals regarding the FDA’s Premarket Tobacco Application (PMTA) rejections. The court upheld the FDA’s Marketing Denial Orders (MDOs), effectively banning their products in the U.S. market.
The ruling reignited debate across the industry: Is it still worth investing millions in PMTA applications? A closer look reveals that beyond technical hurdles, Chinese vape companies face seven deeper structural barriers when trying to break through the FDA’s PMTA wall.
1. Policy Orientation: “Protecting Youth” as Absolute Political Priority
The FDA’s 2024 Enforcement Report is clear: any product that does not “demonstrate no appeal to youth” will be considered a public health threat and subject to permanent bans.
For Chinese firms, the popular “pod-based + flavored” model—once their biggest competitive edge—has become an inherent liability in Washington.
Takeaway: Technical issues can be addressed with data, but political orientation cannot.
2. Burden of Proof Reversal: The FDA Puts the Hardest Work on Companies
Unlike traditional pharmaceuticals, where the government must prove harm, the PMTA process requires companies to prove no harm.
Applicants must demonstrate:
- Potential for misuse in real-world scenarios
- Relative harm reduction compared to cigarettes
- That labeling, marketing, and distribution do not attract minors
Without access to large-scale U.S. consumer data or long-term cohort studies, Chinese companies face what is essentially a “closed-book exam.”
Takeaway: The reversed burden of proof puts late entrants at a structural disadvantage.
3. The Cost Black Hole: Up to $10M per SKU
Official estimates suggest $117,000–$466,000 per product, but real-world costs are far higher. Including toxicology, clinical trials, and environmental assessments, the actual expense per SKU often reaches $8–11M.
One Chinese company reportedly spent $20M on just nine applications—and that figure excludes supplemental trials, legal fees, and U.S. agent costs.
Takeaway: Small and mid-sized firms are priced out, leaving only capital-heavy players.
4. Moving Targets: FDA’s Lack of Clear Standards
The FDA has never published quantitative thresholds for harmful aerosol compounds, abuse potential, or toxicological red lines.
This forces companies to constantly “guess the exam questions.” For example:
- After submitting 90-day animal data, FDA may demand human brain imaging.
- A small change in nicotine concentration can require a full toxicology redo.
Takeaway: Opaque standards turn investments into sunk costs.
5. Procedural Traps: The “Single Deficiency Letter” Rule
Since June 2021, the FDA—facing a backlog of 27M+ applications—adopted a “one letter only” rule: applicants receive a single deficiency letter with 90 days to respond.
This means:
- No second chances
- No “learn as you go”
- No iterative submissions—an approach where Chinese manufacturers typically excel
Takeaway: The process is designed in favor of well-prepared U.S. incumbents familiar with FDA language and expectations.
6. Supply Chain Discrimination: Open-System Devices Under Fire
Both Shenzhen firms that lost their cases were open-system manufacturers, offering devices with refillable tanks and adjustable wattage.
The FDA views these as “uncontrollable misuse risks,” requiring:
- Toxicology data across all wattage levels
- Abuse potential with any nicotine concentration
- Behavioral studies on youth DIY mixing practices
For Shenzhen’s OEM/ODM supply chain—where hardware makers depend on third-party e-liquid brands—this effectively means hardware companies must bear liability for the entire ecosystem.
Takeaway: One misaligned product type can drag down the whole supply chain.
7. Geopolitical & Media Bias: “Made in China” as an Original Sin
The FDA’s 2024 report frequently highlighted Chinese brands for violations. U.S. media often frames the issue as a “Chinese disposable flood.”
Congress members have also proposed tariffs of up to 300% on Chinese Vapes.
When regulatory concerns merge with geopolitics, PMTA becomes more than a scientific process—it becomes a matter of national policy and public sentiment.
Takeaway: Identity politics puts Chinese brands at a disadvantage before the first study is even submitted.
Conclusion: Difficult, But Not Impossible
While the barriers are daunting, strategies for survival do exist:
Technology-Led BreakthroughsFinal Word
PMTA is not a simple product registration—it is a total war spanning laboratories, clinical trials, supply chains, politics, and media narratives.
The defeats of YOUME and IVPS may be the loudest gunfire yet, but they are unlikely to be the last. So far, no Chinese company has completed the full PMTA process.
The ticket to the U.S. market is still being printed. But the price is rising, and the available seats are shrinking.
Whoever passes PMTA will not just gain legal access to the American market—they could become the dominant force in U.S. vaping. For Chinese companies, however, love from Washington will always come with conditions.